Production and Application of CAR T Cells: Current and Future Role of Europe
- PMID: 34490302
- PMCID: PMC8418055
- DOI: 10.3389/fmed.2021.713401
Production and Application of CAR T Cells: Current and Future Role of Europe
Abstract
Rapid developments in the field of CAR T cells offer important new opportunities while at the same time increasing numbers of patients pose major challenges. This review is summarizing on the one hand the state of the art in CAR T cell trials with a unique perspective on the role that Europe is playing. On the other hand, an overview of reproducible processing techniques is presented, from manual or semi-automated up to fully automated manufacturing of clinical-grade CAR T cells. Besides regulatory requirements, an outlook is given in the direction of digitally controlled automated manufacturing in order to lower cost and complexity and to address CAR T cell products for a greater number of patients and a variety of malignant diseases.
Keywords: CAR T cells; automation; cancer treatment; manufacturing; regulation.
Copyright © 2021 Vucinic, Quaiser, Lückemeier, Fricke, Platzbecker and Koehl.
Conflict of interest statement
AQ and PL declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. VV discloses honoraria for Novartis, Gilead, BMS, and travel grants from Gilead. SF states honorary activities for Novartis. With regard to the production of cell therapeutics, there are cooperations with the companies Novartis and Miltenyi Biotec. UP discloses consulting and fee for service activities for Novartis, Gilead and BMS. UK states that she is a consultant in immuno-oncology for AstraZeneca, Affimed, Glycostem, GammaDelta and Zelluna, and that she has collaborations with Novartis and Miltenyi Biotec regarding the production of CAR-T cells.
Figures
Similar articles
-
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital.Front Med (Lausanne). 2022 Jun 6;9:913287. doi: 10.3389/fmed.2022.913287. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35733863 Free PMC article.
-
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.Hum Gene Ther. 2018 May;29(5):559-568. doi: 10.1089/hum.2017.254. Epub 2018 Apr 5. Hum Gene Ther. 2018. PMID: 29620951
-
Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial.Front Immunol. 2020 Mar 20;11:482. doi: 10.3389/fimmu.2020.00482. eCollection 2020. Front Immunol. 2020. PMID: 32528460 Free PMC article. Clinical Trial.
-
Clinical manufacturing of CAR T cells: foundation of a promising therapy.Mol Ther Oncolytics. 2016 Jun 15;3:16015. doi: 10.1038/mto.2016.15. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27347557 Free PMC article. Review.
-
Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts.EMBO Mol Med. 2017 Sep;9(9):1183-1197. doi: 10.15252/emmm.201607485. EMBO Mol Med. 2017. PMID: 28765140 Free PMC article. Review.
Cited by
-
Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma.Front Immunol. 2024 Sep 25;15:1328368. doi: 10.3389/fimmu.2024.1328368. eCollection 2024. Front Immunol. 2024. PMID: 39386211 Free PMC article. Clinical Trial.
-
Updates on CAR T cell therapy in multiple myeloma.Biomark Res. 2024 Sep 12;12(1):102. doi: 10.1186/s40364-024-00634-5. Biomark Res. 2024. PMID: 39261906 Free PMC article. Review.
-
Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development.Front Immunol. 2023 Nov 30;14:1260470. doi: 10.3389/fimmu.2023.1260470. eCollection 2023. Front Immunol. 2023. PMID: 38098489 Free PMC article. Review.
-
Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency.Front Immunol. 2023 Mar 24;14:1086433. doi: 10.3389/fimmu.2023.1086433. eCollection 2023. Front Immunol. 2023. PMID: 37033919 Free PMC article.
-
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input.Cancers (Basel). 2023 Feb 4;15(4):1003. doi: 10.3390/cancers15041003. Cancers (Basel). 2023. PMID: 36831349 Free PMC article. Review.
References
-
- Thomas ED, Lochte HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. (1957) 257:491–6. - PubMed
-
- Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. (2005) 11:945–56. 10.1016/j.bbmt.2005.09.004 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources